Ischemic stroke
Conditions
Interventions
Experimental Group :The experimental group received standard-dose TNK (0.25 mg/kg) thrombolysis concurrent with TCCD monitoring for 30 minutes. Standard therapy was administered in accordance with gui
Control Group:The control group only received standard-dose TNK (0.25 mg/kg)thrombolysis and guideline-directed standard medical therapy.
Sponsors
The First Hospital of Jilin University.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old, gender not limited; 2. It meets the indications for TNK intravenous thrombolytic therapy, and the time from the onset of the disease to the proposed thrombolytic therapy does not exceed 4.5 hours. 3. Diagnostic criteria for posterior circulation cerebral infarction: If MRI examination is performed, the confirmation of posterior circulation infarction by DWI shall be the basis. If imaging vascular examinations are performed, the results of the vascular examinations should be based on the discovery of moderate to severe stenosis of the vertebral and basilar arteries along with typical posterior circulation symptoms and signs. If MRI and vascular examinations have not been performed, a plain CT scan is required without negation, along with typical posterior circulation symptoms and signs. 4. The subject or his/her legal representative agrees to the study and signs the informed consent form for the project.
Exclusion criteria
Exclusion criteria: 1. There are contraindications for thrombolysis; 2. Skull defects and other factors make TCCD monitoring infeasible; 3. Had received other thrombolytic drugs or anticoagulant therapy before enrollment; 4. There is active systemic or visceral bleeding; 5. Patients with severe hematological diseases or coagulation disorders, as well as severe bleeding tendencies; 6. Patients with severe insufficiency of heart, lung, kidney or liver function; 7. Difficulty or refusal to cooperate with the trial and subsequent follow-up visits; 8. Other circumstances that the researcher deems unsuitable for inclusion in the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with Modified Rankin Scale (mRS) Score 0-1 at 90 days;Ordinal distribution of Modified Rankin Scale (mRS);Recanalization rate after thrombolytic therapy;Change in NIHSS scores at 24 hours;Change in NIHSS scores at 7 days;Change in eNIHSS scores at 7 days; | — |
Countries
China
Contacts
Public ContactYang Yi
The First Hospital of Jilin University.
Outcome results
None listed